Does Aetna Cover GLP-1 Weight Loss Drugs? Honest Coverage Review

Short version: Aetna is part of CVS Health, and its pharmacy benefit is administered by its sister company CVS Caremark. That single fact drives almost everything about Aetna weight-loss-drug coverage. GLP-1s for type 2 diabetes (Ozempic, Mounjaro, Trulicity, Rybelsus, Victoza) are widely covered with prior authorization. GLP-1s for chronic weight management (Wegovy, Zepbound, Saxenda) are covered only when your employer elected the anti-obesity-medication benefit — AOM coverage is an employer rider, not a standard inclusion. And the single biggest 2025 event: on July 1, 2025 CVS Caremark dropped Zepbound from its standard commercial formularies and made Wegovy the preferred anti-obesity GLP-1, which flowed straight through to Aetna commercial plans. Then on October 1, 2026 Caremark added Zepbound back as an additional preferred option alongside Wegovy — but only for plan sponsors that adopt the change and cover weight-loss drugs. For Aetna Medicare members, the big 2026 change is federal, not Aetna's: since July 1, 2026 the CMS Medicare GLP-1 Bridge offers eligible Part D enrollees Wegovy, Zepbound KwikPen, or Foundayo for a $50 monthly copay.

At a glance

• Aetna GLP-1 coverage for type 2 diabetes: generally YES with prior authorization. Ozempic, Mounjaro, Trulicity, Rybelsus, and Victoza appear on most Aetna commercial formularies for the T2D indication, adjudicated by CVS Caremark.^[1]
• Aetna GLP-1 coverage for chronic weight management: only if your employer elected the AOM benefit. Wegovy, Zepbound, and Saxenda are covered when the plan includes anti-obesity medications and excluded when the employer carved them out. This is the single biggest determinant of coverage.^[1]
• The 2025 Caremark switch: effective July 1, 2025, CVS Caremark removed Zepbound from its commercial template formularies and made Wegovy the preferred weight-loss GLP-1 after a pricing agreement with Novo Nordisk. Aetna commercial plans following the standard Caremark template inherited that change.^[7][8]
• The 2026 reversal: in a May 28, 2026 announcement, CVS Caremark said it would add Zepbound back to its commercial formularies as an additional preferred option effective October 1, 2026, and remove the new-to-market block on the FDA-approved oral GLP-1 Foundayo (orforglipron) effective June 1, 2026 — both applying only where plan sponsors elect coverage.^[9][18]
• Aetna Medicare (Part D): the Part D plan itself still cannot cover weight-loss-only Wegovy/Zepbound/Saxenda — federal law carries over the Medicaid exclusion list, which names “agents when used for anorexia, weight loss, or weight gain.”^[2] Part D CAN cover the non-weight-loss indications: Zepbound for obstructive sleep apnea, and (formulary-dependent) Wegovy for cardiovascular risk reduction or MASH liver disease.^[5][6]
• Medicare GLP-1 Bridge (new): from July 1, 2026 through December 31, 2027, eligible Part D enrollees — including Aetna Medicare Advantage drug-plan and standalone Part D members — can get Wegovy (injection or tablet), Zepbound KwikPen, or Foundayo for weight loss at a $50 monthly copay. It runs outside the Part D benefit, so Aetna does not have to opt in; a prior authorization and BMI-based eligibility apply.^[13][14]
• Aetna Medicaid (managed care): defers to the state. Aetna Better Health managed-care plans follow each state Medicaid program's preferred drug list and weight-loss-drug rules, which vary widely by state.^[4]
• Typical PA pattern (Wegovy): BMI ≥ 30, OR BMI ≥ 27 with a weight-related comorbidity, age 18+, AND documented participation in a comprehensive weight-management program (behavioral modification, reduced-calorie diet, increased activity) for at least 6 months. Initial approval ~7 months; continuation ~12 months conditioned on ≥5% baseline weight loss.^[3]

Why Aetna coverage is really CVS Caremark coverage

Aetna does not run its own pharmacy benefit. Since CVS Health acquired Aetna in 2018, Aetna's prescription drug benefit has been administered by CVS Caremark, the CVS Health pharmacy-benefit manager (PBM). The practical chain is: Aetna sells the medical plan to your employer, CVS Caremark publishes the formulary and adjudicates prior authorization, and you fill prescriptions at retail pharmacies that submit claims back to Caremark.^[1] For a Caremark-specific breakdown — its preferred formularies, the 2025 Zepbound-to-Wegovy switch, and the 2026 reversal — see does CVS Caremark cover weight-loss drugs.

That means three things for weight-loss-drug coverage:

1. The formulary is a Caremark formulary. Whether Wegovy or Zepbound is preferred, non-preferred, or excluded for weight loss is set by CVS Caremark's rebate-driven formulary strategy — not by Aetna's medical side. When Caremark changed its preferred weight-loss GLP-1 in 2025, Aetna plans on the standard template changed with it.^[7]
2. Prior authorization is adjudicated by Caremark. PA requests route through the CVS Caremark prescriber portal (or fax), not an Aetna-specific portal. The clinical criteria live in Aetna's Pharmacy Clinical Policy Bulletins, which Caremark applies.^[3]
3. Your employer still controls the benefit class. Caremark's standard formulary is a template. Self-funded employers choose whether to include anti-obesity medications at all, and whether to follow the standard formulary or a custom one — and they are most of Aetna's commercial book: about 15.8 million of its 18.3 million commercial medical members were in self-funded (ASC) arrangements as of June 30, 2026.^[15] Two people with “Aetna” cards can have completely different weight-loss-drug coverage.^[1]

GLP-1 coverage for type 2 diabetes (widely covered)

For the type 2 diabetes indication, GLP-1 receptor agonists are generally on-formulary on Aetna commercial plans with prior authorization. The agents commonly covered:

• Ozempic (semaglutide) — once-weekly injection, FDA-approved for T2D + cardiovascular risk reduction in T2D with established CVD. See our semaglutide drug page.
• Mounjaro (tirzepatide) — once-weekly dual GIP/GLP-1, FDA-approved for T2D. See our tirzepatide drug page.
• Trulicity (dulaglutide) — once-weekly GLP-1, FDA-approved for T2D + CV risk reduction.
• Rybelsus (oral semaglutide) — daily oral tablet, FDA-approved for T2D.
• Victoza (liraglutide) — daily GLP-1, FDA-approved for T2D; older agent with branded and authorized-generic forms.

Typical Aetna/Caremark PA criteria for a T2D GLP-1: a confirmed T2D diagnosis (ICD-10 E11.x), a documented A1C, usually a trial of metformin (or documented intolerance/contraindication), and prescriber documentation of treatment goals. Because T2D is not a weight-loss indication, these drugs sit on the diabetes side of the formulary and are not affected by the AOM-rider question.^[1]

GLP-1 coverage for chronic weight management (employer rider)

This is where Aetna coverage becomes conditional. The FDA-approved anti-obesity GLP-1-class drugs — Wegovy (semaglutide; weekly injection and once-daily tablets; labeled for chronic weight management, cardiovascular risk reduction in adults with established CVD, and — injection only, under accelerated approval — noncirrhotic MASH with F2–F3 liver fibrosis^[5]), Zepbound (tirzepatide; chronic weight management + moderate-to-severe OSA in adults with obesity^[6]), Foundayo (orforglipron, a once-daily oral GLP-1 for chronic weight management^[18]), and Saxenda (liraglutide 3.0 mg) — are covered by Aetna for weight loss only when the employer plan includes the anti-obesity-medication benefit.

AOM coverage is not a standard inclusion. It is effectively a rider that the plan sponsor (your employer, or for individual plans the plan design itself) elects to buy. Many employers carve anti-obesity medications out of the prescription benefit entirely to control premium cost — and when they do, no amount of medical-necessity documentation will produce coverage, because the benefit class itself is excluded.^[1]

When the plan does include AOMs, Aetna's published Wegovy PA criteria are well-defined:^[3]

• BMI ≥ 30 kg/m², OR BMI ≥ 27 kg/m² with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, or — for the Zepbound OSA pathway — moderate-to-severe obstructive sleep apnea).
• Age 18 or older for the weight-management indication (12–17 for the pediatric obesity pathway). The separate Wegovy cardiovascular pathway requires established cardiovascular disease (prior heart attack, stroke, or symptomatic peripheral artery disease), BMI ≥ 27, and no type 2 diabetes — Ozempic covers that case.
• Documented participation in a comprehensive weight-management program — behavioral modification, reduced-calorie diet, and increased physical activity with follow-up — for at least 6 months prior to the request.
• Initial approval is typically 7 months; continuation is typically 12 months, conditioned on maintaining at least 5% baseline weight loss (or ongoing weight reduction). Quantity limits apply (one 4-pen carton per 28-day fill, or three per 84-day fill).

For the underlying weight-loss magnitudes that anchor these PA decisions, see our best semaglutide providers and best tirzepatide providers rankings.

The 2025 Caremark Zepbound-to-Wegovy switch (and the 2026 reversal)

The most consequential change to Aetna weight-loss coverage in years did not originate on Aetna's medical side at all — it came from the PBM. Effective July 1, 2025, CVS Caremark removed Zepbound (tirzepatide) from its commercial template formularies — the standard lists most of its employer clients use — and designated Wegovy (semaglutide 2.4 mg) as the preferred anti-obesity GLP-1, after partnering with Novo Nordisk on a lower price.^[7][8]

For Aetna commercial members on plans following the standard Caremark template, the practical effect was: if your employer included AOM coverage, Wegovy was the covered weight-loss GLP-1 and Zepbound was no longer covered for weight loss as of July 1, 2025. Members already on Zepbound generally had to switch to Wegovy or pursue a formulary exception (for example, documented intolerance or insufficient response to Wegovy). For dose-conversion context when switching tirzepatide-to-semaglutide, talk to your prescriber before changing agents.

On May 28, 2026, CVS Caremark announced a partial reversal: Zepbound would return to its commercial formularies as an additional preferred option effective October 1, 2026, putting Wegovy and Zepbound side-by-side for plan sponsors that elect weight-loss coverage. Separately, Caremark removed the new-to-market block on Foundayo (orforglipron, an oral GLP-1) effective June 1, 2026, where plans approve coverage. CVS framed both moves as the result of negotiating lower prices with the manufacturers, and noted that plan sponsors using its template formularies keep discretion to customize coverage.^[9]

Aetna Medicare (Part D) — federal exclusion

Aetna is one of the largest Medicare Part D and Medicare Advantage carriers in the country. Like every Medicare Part D plan, Aetna Medicare operates under Social Security Act §1860D-2(e)(2)(A), which excludes from Part D the drug uses that Medicaid may exclude under §1927(d)(2) — a list that begins with “agents when used for anorexia, weight loss, or weight gain.”^[2] This is a federal statutory exclusion — an Aetna Medicare Part D plan cannot cover Wegovy, Zepbound, or Saxenda for weight-loss-only indications regardless of medical-necessity documentation. (The new Medicare GLP-1 Bridge, below, works around this by paying outside the Part D benefit.)

Four exceptions where an Aetna Medicare Part D plan CAN cover otherwise-excluded GLP-1s:

• Ozempic / Mounjaro / Trulicity for T2D. T2D is not a weight-loss indication, so the §1860D-2(e)(2)(A) exclusion does not apply.
• Zepbound for moderate-to-severe obstructive sleep apnea. The FDA approved this distinct indication on December 20, 2024. The Zepbound label (SetID 487cd7e7-434c-4925-99fa-aa80b1cc776b^[6]) lists OSA in adults with obesity as a separately FDA-approved indication — and because it is not weight loss, the Part D exclusion does not block coverage. Aetna Medicare can cover Zepbound for OSA subject to PA. The SURMOUNT-OSA trial is the underlying evidence base.^[10]
• Wegovy for cardiovascular risk reduction. Wegovy's second FDA-approved indication is reducing the risk of major adverse cardiovascular events in adults with established CVD and overweight/obesity.^[5] As a non-weight-loss indication, this is coverable on Medicare Part D — though individual Aetna Medicare formularies vary on how aggressively they cover it. Confirm with your specific plan's formulary.
• Wegovy for MASH. Wegovy injection is also FDA-approved, under accelerated approval, for noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced (F2–F3) liver fibrosis in adults.^[5] That is a liver indication, not weight loss, so it is coverable on Part D subject to the plan's formulary and PA; Medicare.gov directs people with fatty liver disease to their Part D plan rather than the GLP-1 Bridge.^[14]

The Medicare GLP-1 Bridge — $50/month for eligible Aetna Medicare members

Starting July 1, 2026, CMS runs a short-term demonstration called the Medicare GLP-1 Bridge, now extended through December 31, 2027. It operates outside the Part D benefit's coverage and payment flow, so Part D sponsors such as Aetna carry no risk and do not have to opt in: a single CMS central processor handles prior authorization and pays pharmacies. Eligible beneficiaries pay a $50 copay; the Part D deductible does not apply, the copay does not count toward the annual out-of-pocket cap, and Extra Help (LIS) does not reduce it.^[13]

• Who can use it: people with Medicare drug coverage — standalone Part D, Medicare Advantage drug plans (HMO/PPO), Special Needs Plans, and employer/union group waiver plans — which covers Aetna's Medicare Advantage and Part D members.^[14]
• Covered drugs: Wegovy (injection or tablet), Zepbound KwikPen (not single-dose vials or pens), and Foundayo.^[14]
• Clinical eligibility (age 18+, at the start of GLP-1 therapy): BMI ≥ 35; or BMI ≥ 30 with heart failure with preserved ejection fraction, uncontrolled hypertension, or chronic kidney disease stage 3a+; or BMI ≥ 27 with prediabetes, a prior heart attack or stroke, or symptomatic peripheral artery disease. Your prescriber must certify use alongside a diet-and-exercise lifestyle program.^[14]
• Who is excluded: people already getting a GLP-1 through their Part D plan, and people with type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease — those indications go through the regular Aetna Part D formulary instead.^[14]

Aetna Medicaid managed care — defers to the state

Aetna participates in Medicaid managed care through Aetna Better Health plans in numerous states. For Medicaid managed-care members, weight-loss-drug coverage is governed by the state Medicaid program, not by Aetna's commercial formulary. Each state decides whether its Medicaid program covers anti-obesity GLP-1s, and the rules vary widely — some states cover Wegovy/Zepbound for weight loss with PA, others exclude weight-loss GLP-1s entirely while continuing to cover the T2D indication.^[4]

Aetna Better Health plans follow the applicable state Medicaid preferred drug list and PA criteria. If you have an Aetna Better Health Medicaid plan, the authoritative source is your state Medicaid program's drug coverage rules combined with your Aetna Better Health formulary — not Aetna's commercial documents.

How to find out if YOUR Aetna plan covers Wegovy or Zepbound

Four reliable ways, in order from fastest to most authoritative:

1. CVS Caremark member portal → drug-cost / formulary lookup. Because Aetna's pharmacy benefit is administered by CVS Caremark, the canonical formulary tool is the Caremark portal (or the Aetna member site, which links to it). Sign in, search “Wegovy” or “Zepbound,” and the result shows the tier, PA requirement, and whether the AOM benefit applies to your plan.^[1]
2. Phone the number on your Aetna/Caremark card. Ask specifically: “Does my plan include anti-obesity-medication coverage? Is (drug name) covered for chronic weight management, what tier, and what is the PA requirement?” The AOM-rider question is the one that matters most.
3. Ask your HR or benefits administrator about the AOM rider. For employer-sponsored plans, HR knows whether the plan bought anti-obesity-medication coverage and whether it follows the standard Caremark formulary or a custom one. This is often faster than the portal for the rider question.
4. Request the Summary of Benefits and Coverage (SBC) and the prescription-drug rider. The SBC and drug rider state whether AOMs are an excluded benefit class. If they are excluded, that is dispositive.

Prior authorization process at Aetna (via CVS Caremark)

Because the benefit is PBM-administered, the PA flow runs through CVS Caremark:

1. Your prescriber evaluates you against Aetna's published Pharmacy Clinical Policy Bulletin criteria (BMI ≥ 30, or ≥ 27 with comorbidity, age 18+, plus the documented 6-month comprehensive weight-management program for Wegovy/Zepbound).^[3]
2. If criteria are met, the prescriber submits the PA through the CVS Caremark prescriber portal (electronic PA) or by fax to Caremark — not an Aetna-specific portal.
3. CVS Caremark adjudicates the PA against Aetna's clinical criteria. Standard turnaround is typically within a few business days for non-urgent requests; expedited review is available for urgent cases.
4. If approved, you fill at a participating retail or mail-order pharmacy and the plan copay/tier applies. Initial approval is typically 7 months; continuation requires documented ≥5% baseline weight loss.^[3]

If denied: Aetna appeal pathway

Aetna commercial members have a defined appeal pathway plus an external review track:

1. First-level internal appeal. You or your prescriber submit a written appeal within the timeframe on the denial notice (commonly 180 days for commercial plans), adding clinical documentation — for example, the 6-month weight-management program records, comorbidity documentation, or evidence of intolerance/insufficient response to the preferred agent (relevant for a Wegovy-vs-Zepbound exception request).
2. Second-level internal appeal if the first is upheld, typically reviewed by a different clinician.
3. External review (IRO). If internal appeals are exhausted, fully-insured commercial members can request an independent external review by an Independent Review Organization, generally binding on the plan; the pathway routes through the relevant state insurance regulator's external-review program.
4. ERISA self-funded plans. For the large share of Aetna members on self-funded employer plans, appeals follow ERISA's federal framework, and the employer plan sponsor's terms govern — including whether the AOM benefit exists at all. If AOMs are a carved-out benefit class, that is a plan-design exclusion, not a medical-necessity denial, and is generally not appealable on clinical grounds.

If Aetna denies or excludes — what actually works

Ranked by cost, the practical alternatives while you appeal or if your plan permanently excludes AOMs:

• Request a formulary exception (the Wegovy/Zepbound switch case). If your plan covers one preferred weight-loss GLP-1 and you cannot tolerate it or it did not work, your prescriber can request a formulary exception for the non-preferred agent with documentation. This is the most common path for members caught in the 2025 Caremark switch.
• Compounded tirzepatide or semaglutide via verified 503A telehealth. Typically $149-$349/month. Not brand Wegovy or Zepbound — the active ingredient is the same, but quality and supply-chain rigor vary. Diligence matters.
• Manufacturer self-pay. Lilly lists Zepbound KwikPen self-pay at $299 (2.5 mg), $399 (5 mg), $499 (7.5 mg), and $699 (10–15 mg) per month, with an on-time-refill offer as low as $449 for 7.5 mg and up; 2.5 mg vials are also $299.^[16] Novo Nordisk lists Wegovy pens at $349/month ($199 for the first two fills at 0.25/0.5 mg for new patients through 2026) and Wegovy tablets from $149/month (1.5 mg) to $299/month (9 and 25 mg).^[17] Cash-pay; no insurance involvement.
• The Zepbound OSA pathway. If you have a moderate-to-severe OSA diagnosis (AHI ≥ 15), your prescriber can submit a Zepbound PA for the OSA indication, not weight loss — including on Aetna Medicare, where the Part D weight-loss exclusion does not apply.^[6]
• Wegovy for cardiovascular risk reduction. If you have established CVD plus overweight/obesity, your prescriber can submit a Wegovy PA for the CV-risk-reduction indication — a non-weight-loss indication coverable even on Medicare.^[5]
• Medicare GLP-1 Bridge (Aetna Medicare members). If you meet the BMI-and-condition criteria and don't have type 2 diabetes, sleep apnea, or fatty liver disease, your prescriber can start Wegovy, Zepbound KwikPen, or Foundayo through the Bridge at $50/month through December 31, 2027.^[14]
• Compare other payers. For how an integrated HMO handles the same drugs differently, see our Kaiser Permanente weight-loss-drug coverage review, and our broader insurance coverage hub.

For mechanism-of-action context and the underlying weight-loss magnitudes (STEP-1 semaglutide 2.4 mg −14.9% body weight at 68 weeks vs −2.4% with placebo^[11]; SURMOUNT-1 tirzepatide 15 mg −20.9% at 72 weeks vs −3.1% with placebo^[12]), and provider options, see our best semaglutide providers and best tirzepatide providers rankings, plus the semaglutide and tirzepatide drug pages.

Verdict — what most Aetna members should expect

For the median Aetna member asking does Aetna cover weight loss drugs: the answer splits cleanly by indication and by whether your employer bought the AOM benefit:

1. T2D GLP-1s (Ozempic, Mounjaro, Trulicity, Rybelsus, Victoza): generally YES with CVS Caremark prior authorization confirming the T2D diagnosis.
2. Chronic-weight-management GLP-1s (Wegovy, Zepbound, Saxenda): only if your employer elected the anti-obesity-medication rider. From July 1, 2025 the Caremark template formularies preferred Wegovy and dropped Zepbound; since October 1, 2026 Zepbound is back as an additional preferred option — but only for plan sponsors that adopt the change. Foundayo is coverable where the plan approves it. Verify on the CVS Caremark portal.
3. Aetna Medicare members: the Part D plan still excludes weight-loss-only use, but eligible members can get Wegovy, Zepbound KwikPen, or Foundayo for $50/month through the federal Medicare GLP-1 Bridge (July 1, 2026–December 31, 2027). Part D covers Zepbound for OSA and, formulary-dependent, Wegovy for CV-risk reduction or MASH.
4. Aetna Better Health Medicaid members: defers to your state Medicaid program's rules — varies widely by state.

The PBM-administered model means the formulary is a moving target driven by rebate negotiations — the 2025 Zepbound drop and the 2026 return of Zepbound as an additional preferred option are the clearest example in recent memory. The single most important question for any Aetna member is not “is the drug on the formulary” but “did my employer include the anti-obesity-medication benefit at all.”

Further reading

• Does Kaiser Permanente cover weight-loss drugs?
• GLP-1 insurance coverage hub